Rein Therapeutics financials
$0.7900+9.57%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$6.1M | -$5.2M | -$32.7M | -$5.5M | -$6.9M | -$5.6M |
| Net income | -$6.4M | -$5.8M | -$32.0M | -$5.6M | -$6.8M | -$5.5M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-0.10 | $-0.19 | $-1.09 | $-0.21 | $-0.28 | $-0.25 |
| EBITDA | -$6.1M | -$5.2M | -$4.0M | -$5.5M | -$6.9M | -$5.6M |
| Operating cash flow | -$8.6M | -$3.4M | -$3.2M | -$3.5M | -$6.4M | -$6.2M |
| Free cash flow | -$8.6M | -$3.4M | -$3.2M | -$3.5M | -$6.4M | -$6.2M |
| Diluted shares | 67.1M | 30.4M | 29.3M | 26.4M | 24.2M | 21.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.5M | $4.4M | $3.2M | $4.0M | $5.7M | $7.4M |
| Short-term investments | $32.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $4.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $66.0M | $26.3M | $24.2M | $53.7M | $57.5M | $57.6M |
| Total liabilities | $10.8M | $14.7M | $7.2M | $7.5M | $9.5M | $7.7M |
| Shareholders' equity | $10.2M | -$33.4M | -$28.1M | $1.2M | $3.0M | $4.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology